220 related articles for article (PubMed ID: 25902888)
21. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
22. Isoquercitrin protects against pulmonary hypertension via inhibiting PASMCs proliferation.
Zhang Y; Cui Y; Deng W; Wang H; Qin W; Huang C; Li C; Zhang J; Guo Y; Wu D; Guo H
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):362-370. PubMed ID: 27873355
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
24. Reversal of experimental pulmonary hypertension by PDGF inhibition.
Schermuly RT; Dony E; Ghofrani HA; Pullamsetti S; Savai R; Roth M; Sydykov A; Lai YJ; Weissmann N; Seeger W; Grimminger F
J Clin Invest; 2005 Oct; 115(10):2811-21. PubMed ID: 16200212
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
26. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
[TBL] [Abstract][Full Text] [Related]
27. Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.
Zhu R; Bi L; Kong H; Xie W; Hong Y; Wang H
Int J Clin Exp Pathol; 2015; 8(10):12169-76. PubMed ID: 26722401
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
Hadri L; Kratlian RG; Benard L; Maron BA; Dorfmüller P; Ladage D; Guignabert C; Ishikawa K; Aguero J; Ibanez B; Turnbull IC; Kohlbrenner E; Liang L; Zsebo K; Humbert M; Hulot JS; Kawase Y; Hajjar RJ; Leopold JA
Circulation; 2013 Jul; 128(5):512-23. PubMed ID: 23804254
[TBL] [Abstract][Full Text] [Related]
29. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
30. eIF2α promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats.
Guo L; Li Y; Tian Y; Gong S; Chen X; Peng T; Wang A; Jiang Z
Drug Des Devel Ther; 2019; 13():2799-2809. PubMed ID: 31496656
[TBL] [Abstract][Full Text] [Related]
31. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension.
Nogueira-Ferreira R; Ferreira-Pinto MJ; Silva AF; Vitorino R; Justino J; Costa R; Moreira-Gonçalves D; Quignard JF; Ducret T; Savineau JP; Leite-Moreira AF; Ferreira R; Henriques-Coelho T
J Cell Physiol; 2017 Nov; 232(11):3128-3138. PubMed ID: 28036116
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
Houssaini A; Abid S; Mouraret N; Wan F; Rideau D; Saker M; Marcos E; Tissot CM; Dubois-Randé JL; Amsellem V; Adnot S
Am J Respir Cell Mol Biol; 2013 May; 48(5):568-77. PubMed ID: 23470622
[TBL] [Abstract][Full Text] [Related]
33. LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT
Su H; Xu X; Yan C; Shi Y; Hu Y; Dong L; Ying S; Ying K; Zhang R
Respir Res; 2018 Dec; 19(1):254. PubMed ID: 30547791
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
36. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition.
Cantoni S; Galletti M; Zambelli F; Valente S; Ponti F; Tassinari R; Pasquinelli G; Galiè N; Ventura C
FEBS J; 2013 May; 280(9):2042-55. PubMed ID: 23463962
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.
Liu HM; Jia Y; Zhang YX; Yan J; Liao N; Li XH; Tang Y
Acta Pharmacol Sin; 2019 Apr; 40(4):477-485. PubMed ID: 30038339
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Zhao L; Ashek A; Wang L; Fang W; Dabral S; Dubois O; Cupitt J; Pullamsetti SS; Cotroneo E; Jones H; Tomasi G; Nguyen QD; Aboagye EO; El-Bahrawy MA; Barnes G; Howard LS; Gibbs JS; Gsell W; He JG; Wilkins MR
Circulation; 2013 Sep; 128(11):1214-24. PubMed ID: 23900048
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats.
Dai YP; Bongalon S; Tian H; Parks SD; Mutafova-Yambolieva VN; Yamboliev IA
Vascul Pharmacol; 2006 May; 44(5):275-82. PubMed ID: 16524786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
